Coya Therapeutics Advances ALS and FTD Trials with Fast Track Designation — Coya Therapeutics, Inc.

Event summary

Coya Therapeutics completed the first cohort of patients in the ALSTARS Phase 2 ALS trial, progressing into a 24-week blinded active treatment extension phase.
The company received FDA Fast Track Designation for COYA 302, aimed at treating ALS and FTD.
Cash reserves stood at $43.2 million as of June 30, 2026, sufficient to fund operations into the second half of 2027.
Research and development expenses increased by $1.3 million year-over-year due to advancements in the COYA 302 ALS Phase 2 clinical trial.

The big picture

Coya Therapeutics is leveraging Treg biology to address neurodegenerative diseases like ALS and FTD, a niche but growing area within biotech focused on immunomodulatory therapies. The FDA Fast Track Designation for COYA 302 underscores the unmet medical need in these conditions, potentially positioning Coya as a key player in this space. However, the company's ability to execute on multiple trials simultaneously will be critical to its long-term success.

What we're watching

Trial Execution: Whether Coya can sustain the momentum in enrolling patients for both ALS and FTD trials, ensuring timely topline data readouts.
Regulatory Advantage: How the FDA Fast Track Designation will accelerate COYA 302's development timeline and potential market entry.
Financial Runway: The pace at which Coya Therapeutics burns through its $43.2 million cash reserves, given increased R&D expenses.